source
- PepGen soars on promising early data for muscular dystrophy drugWhile from a small study, the findings suggest PepGen’s therapy compares favorably to other RNA-based medicines in testing at Novartis and Dyne Therapeutics.BioPharma Dive · 2d ago↗ source
- Delix raises $100M to advance at-home psychedelic without hallucinogenic effectsThe series C raise, co-led by Johnson & Johnson’s venture capital arm, will help Delix Therapeutics push its novel psychedelic asset into mid-stage development for major depressive disorder.BioSpace · 3d ago↗ source
- Recon: Bayer wins FDA approval for stroke prevention drug; Third Rock enters $2B partnership with AI-focused Chinese biotechWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.